Relationship between Microsatellite Instability, Immune Cells Infiltration, and Expression of Immune Checkpoint Molecules in Ovarian Carcinoma: Immunotherapeutic Strategies for the Future.
Adult
Aged
Antineoplastic Agents, Immunological
/ pharmacology
Biomarkers, Tumor
Disease Susceptibility
Female
Gene Expression Regulation, Neoplastic
/ drug effects
Humans
Immunomodulation
/ genetics
Lymphocytes, Tumor-Infiltrating
/ immunology
Microsatellite Instability
Middle Aged
Molecular Targeted Therapy
Neoplasm Grading
Neoplasm Staging
Ovarian Neoplasms
/ etiology
Prognosis
T-Lymphocyte Subsets
/ immunology
immune checkpoint inhibitor
immunohistochemistry
microsatellite instability
mismatch repair protein
ovarian cancer
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
16 Oct 2019
16 Oct 2019
Historique:
received:
28
08
2019
revised:
11
10
2019
accepted:
11
10
2019
entrez:
19
10
2019
pubmed:
19
10
2019
medline:
27
2
2020
Statut:
epublish
Résumé
Ovarian cancer has the worst prognosis among gynecological cancers. Thus, new ovarian cancer treatment strategies are needed. Currently, immune checkpoint inhibitors such as anti-PD-1/PD-L1 antibody are attracting attention worldwide. The Food and Drug Administration approved the use of the PD-1 antibody pembrolizumab for solid cancers with microsatellite instability (MSI)-H or mismatch repair (MMR) deficiency in 2017. However, few studies on ovarian carcinoma have evaluated the relationship among MSI status, lymphocyte infiltration into the tumor, and the expression of immune checkpoint molecules by histologic type. We evaluated the expression of MMR proteins, tumor-infiltrating lymphocytes (CD8+), and immune checkpoint molecules (PD-L1/PD-1) by immunohistochemistry in 136 ovarian cancer patients (76, 13, 23, and 24 cases were high-grade serous, mucinous, endometrioid, and clear cell carcinoma, respectively) to investigate the effectiveness of immune checkpoint inhibitors. Only six cases (4.4%) had loss of MMR protein expression. There was no significant relationship between MSI status and age (
Identifiants
pubmed: 31623180
pii: ijms20205129
doi: 10.3390/ijms20205129
pmc: PMC6829575
pii:
doi:
Substances chimiques
Antineoplastic Agents, Immunological
0
Biomarkers, Tumor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Blood. 2010 Nov 25;116(22):4501-11
pubmed: 20682852
Science. 2011 Mar 25;331(6024):1565-70
pubmed: 21436444
N Engl J Med. 2010 Oct 14;363(16):1532-43
pubmed: 20942669
N Engl J Med. 2009 Jul 9;361(2):170-7
pubmed: 19587342
Am J Surg Pathol. 2008 Jul;32(7):1029-37
pubmed: 18469706
Clin Cancer Res. 2017 Jul 15;23(14):3711-3720
pubmed: 28167507
Lancet. 2016 Apr 9;387(10027):1540-1550
pubmed: 26712084
Oncol Rep. 2008 Mar;19(3):775-81
pubmed: 18288415
Nat Immunol. 2002 Nov;3(11):991-8
pubmed: 12407406
Clin Cancer Res. 2016 Jun 15;22(12):3025-36
pubmed: 27306793
Cancer Res. 2004 Nov 1;64(21):7678-81
pubmed: 15520168
Breast Cancer Res Treat. 2015 Jun;151(3):629-38
pubmed: 26006067
Am J Surg Pathol. 2007 Feb;31(2):161-9
pubmed: 17255760
N Engl J Med. 2015 Jun 25;372(26):2509-20
pubmed: 26028255
Clin Cancer Res. 2014 Oct 1;20(19):5064-74
pubmed: 24714771
N Engl J Med. 2016 Dec;375(22):2154-2164
pubmed: 27717299
N Engl J Med. 2012 Jun 28;366(26):2443-54
pubmed: 22658127
Histopathology. 2013 Jan;62(1):59-70
pubmed: 23240670
J Clin Oncol. 2004 Mar 15;22(6):1040-4
pubmed: 15020606
Lancet Oncol. 2011 Sep;12(9):852-61
pubmed: 21862407
Gynecol Oncol. 2018 Apr;149(1):146-154
pubmed: 29496294
Am Soc Clin Oncol Educ Book. 2019 Jan;39:e126-e140
pubmed: 31099679
Histopathology. 2016 Aug;69(2):288-97
pubmed: 26799366
Oncotarget. 2017 Dec 31;9(5):5652-5664
pubmed: 29464025
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
Lancet. 2018 Mar 17;391(10125):1023-1075
pubmed: 29395269
N Engl J Med. 2016 Jun 30;374(26):2542-52
pubmed: 27093365
Br J Cancer. 2018 Apr;118(7):933-935
pubmed: 29531322
Clin Cancer Res. 2016 Aug 15;22(16):4215-24
pubmed: 27006490
Int J Gynaecol Obstet. 2014 Jan;124(1):1-5
pubmed: 24219974
Oncoimmunology. 2018 Nov 20;8(2):e1541535
pubmed: 30713802
Int Immunol. 2010 Aug;22(8):651-60
pubmed: 20587542
Int J Cancer. 2010 Aug 15;127(4):759-67
pubmed: 20518016
Nature. 2013 Aug 22;500(7463):415-21
pubmed: 23945592
Eur J Obstet Gynecol Reprod Biol. 2008 Jun;138(2):187-93
pubmed: 18162283
Gynecol Oncol. 2006 Aug;102(2):285-91
pubmed: 16516283
Cancer Res. 2015 Dec 1;75(23):5034-45
pubmed: 26573793
Proc Natl Acad Sci U S A. 2013 Oct 29;110(44):17945-50
pubmed: 24127572
Lancet Oncol. 2014 Jul;15(8):852-61
pubmed: 24882434
Oncoimmunology. 2017 Jan 6;6(2):e1277308
pubmed: 28344892
Beijing Da Xue Xue Bao Yi Xue Ban. 2006 Feb 18;38(1):62-5
pubmed: 16415969
Science. 2018 Feb 2;359(6375):582-587
pubmed: 29217585
Br J Cancer. 2015 Jul 14;113(2):299-310
pubmed: 26172027
Int J Gynaecol Obstet. 2006 Nov;95 Suppl 1:S161-92
pubmed: 17161157
Am J Surg Pathol. 2012 Feb;36(2):163-72
pubmed: 22189970